The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
== Photosynthesis == In order to conduct photosynthesis, Roseiflexus castenholzii contains three different complexes: light-harvesting only (LH), reaction center only (RC) and light-harvesting with reaction center (LHRC). In contrast to most other FAPs, R. castenholzii does not have chlorosomes, which contain great amounts of photosynthetic pigments. Because chlorosomes can obstruct observations of photosynthetic complexes, Roseiflexus castenholzii is considered a model organism to study the reaction centers FAPs have. The LHRC contains both light harvesting and reaction center peptides that allow for absorbing light and exciting electrons in one complex. The light-harvesting complex contains antenna pigments that allow the bacterium to absorb light around 800 nanometers. The majority of these pigments are bacteriochlorophyll (BChl). The reaction center in Roseiflexus castenholzii is closely related to the RC of Chloroflexus aurantiacus. R. castenholzii's RC complex contains three subunits: L, M, and a c-type cytochrome. It lacks the H subunit common in purple bacteria. The RC also contains BChl and bacteriopheophytin (BPhe) pigments.
Evolution of Aschoff nodules typically involve 3 stages of development all of which may be present in the heart at the same time of inspection. Stage 1. Early exudative / degenerative stage the earliest sign of injury to the heart in rheumatic fever is apparent by fourth week of illness. Initially there is edema of the connective tissue and increase in acid mucopolysaccharide in the ground substance. This results in a separation of the collagen fibre by accumulating ground substance eventually the collagen fibres are fragmented and disintegrated and the affected focus takes the appearance and staining characteristics of fibrin. Stage 2. Intermediate proliferative / granulomatous stage. It is at this stage of Aschoff bodies, which is pathognomonic of rheumatic fever. This stage is apparent in 4 to 13 weeks of illness. The early stage of fibrinoid change is replaced by infiltration of lymphocyte T cells, plasma cells, neutrophils and the characteristic cardiac histiocytes / Anitschkow cells at the margin of the lesion. Cardiac Histiocytes / Anitschkow are present in small numbers in the heart but their numbers are increased in Aschoff nodules. therefore they are not characteristic of rheumatic heart disease Stage 3. Late fibrosis stage. It is the stage of healing by which the fibrosis of the Aschoff nodules occur in 12 to 16 weeks after the illness. The nodule becomes oval or fusiform in shape about 200 micrometer x 600 micrometer in width and length. With passage of months and years the Aschoff nodules becomes less cellular and collagenous tissue is increased.
=== Water treatment === Metal–organic frameworks (MOFs) have attracted increasing attention as functional materials for water treatment due to their high surface area, tunable pore structures, and chemical versatility. These properties enable MOFs to act as efficient platforms for the removal of a wide range of contaminants from aqueous systems. In particular, MOFs have been extensively investigated for the adsorption of heavy metal ions such as lead, chromium, arsenic, and cadmium , as well as for the removal of organic pollutants including dyes, pesticides, and pharmaceutical residues. In water treatment applications, adsorption is one of the primary mechanisms by which MOFs operate. The porous structure of MOFs provides abundant active sites for interaction with pollutants, while the ability to tailor the chemical functionality of the framework allows for selective binding through coordination interactions, electrostatic attraction, and hydrogen bonding. This tunability has enabled the design of MOFs with enhanced selectivity toward specific contaminants, making them promising candidates for targeted water purification. Beyond adsorption, MOFs have also been explored in membrane-based separation processes and as catalytic materials for the degradation of pollutants. For example, MOF-based membranes have demonstrated potential for selective ion separation and removal of dissolved contaminants, while photocatalytic and advanced oxidation processes involving MOFs have been used to degrade persistent organic pollutants into less harmful species.
Sources: en.wikipedia.org
While a variety of theories have been postulated for the etymological origins of Canada, the name is now accepted as coming from the St. Lawrence Iroquoian word kanata, meaning 'village' or 'settlement'. In 1535, Indigenous inhabitants of the present-day Quebec City region used the word to direct French explorer Jacques Cartier to the village of Stadacona. Cartier later used the word Canada to refer not only to that particular village but to the entire area subject to Donnacona (the chief at Stadacona); by 1545, European books and maps had begun referring to this small region along the Saint Lawrence River as Canada. From the 16th to the early 18th century, Canada referred to the part of New France that lay along the Saint Lawrence River. Following the British conquest of New France, this area was known as the British Province of Quebec from 1763 to 1791. In 1791, the area became two British colonies called Upper Canada and Lower Canada. These two colonies were collectively referred to as the Canadas until their union as the Province of Canada in 1841. Upon Confederation in 1867, Canada was adopted as the legal name for the new country at the London Conference and the word dominion was conferred as the country's title, reflecting its status as a self-governing nation within the British Empire.
Adverse reaction Adverse event Adverse drug reaction Biosecurity Biosecurity in the United States Drug Efficacy Study Implementation Food and Drug Administration Modernization Act of 1997 FDA Food Safety Modernization Act of 2011 FDA Fast Track Development Program (for drugs) Food and Drug Administration Amendments Act of 2007 (e.g. drugs) Food and Drug Administration Safety and Innovation Act of 2012 (GAIN/QIDP etc.) Inverse benefit law Investigational Device Exemption (for use in clinical trials) Kefauver Harris Amendment 1962 – required "proof-of-efficacy" for drugs International:
{\displaystyle \mu ={\frac {1}{j+1}}{\Bigl \langle }(l,s),j,m_{j}{=}j\,{\Bigr |}\left({\frac {1}{2}}{\vec {l}}{g^{(l)}}_{p}+{\frac {1}{2}}{\vec {s}}({g^{(s)}}_{p}+{g^{(s)}}_{n})\right)\cdot {\vec {\jmath }}\,{\Bigl |}\,(l,s),j,m_{j}{=}j{\Bigr \rangle }}
==== Absorption and distribution ==== Fomepizole distributes rapidly into total body water. The volume of distribution is between 0.6 and 1.02 L/kg. The therapeutic concentration is from 8.2 to 24.6 mg (100 to 300 micromoles) per liter. Peak concentration following single oral doses of 7 to 50 mg/kg of body weight occurred in 1 to 2 hours. The half-life varies with dose, so has not been calculated.
Sources: en.wikipedia.org
== Column adsorption equilibrium == For an adsorption column, the column resin (the stationary phase) is composed of microbeads. Even smaller particles such as proteins, carbohydrates, metal ions, or other chemical compounds are conjugated onto the microbeads. Each binding particle that is attached to the microbead can be assumed to bind in a 1:1 ratio with the solute sample sent through the column that needs to be purified or separated. Binding between the target molecule to be separated and the binding molecule on the column beads can be modeled using a simple equilibrium reaction Keq = [CS]/([C][S]) where Keq is the equilibrium constant, [C] and [S] are the concentrations of the target molecule and the binding molecule on the column resin, respectively. [CS] is the concentration of the complex of the target molecule bound to the column resin. Using this as a basis, three different isotherms can be used to describe the binding dynamics of a column chromatography: linear, Langmuir, and Freundlich. The linear isotherm occurs when the solute concentration needed to be purified is very small relative to the binding molecule. Thus, the equilibrium can be defined as:
Bacteria resist phage infection through restriction modification systems that degrade foreign DNA and a system that uses CRISPR sequences to retain fragments of the genomes of phage that the bacteria have come into contact with in the past, which allows them to block virus replication through a form of RNA interference. Third, bacteria can transfer genetic material through direct cell contact via conjugation. In ordinary circumstances, transduction, conjugation, and transformation involve transfer of DNA between individual bacteria of the same species, but occasionally transfer may occur between individuals of different bacterial species, and this may have significant consequences, such as the transfer of antibiotic resistance. In such cases, gene acquisition from other bacteria or the environment is called horizontal gene transfer and may be common under natural conditions.
The volatility of bromine accentuates its very penetrating, choking, and unpleasant odour. All four stable halogens experience intermolecular van der Waals forces of attraction, and their strength increases together with the number of electrons among all homonuclear diatomic halogen molecules. Thus, the melting and boiling points of bromine are intermediate between those of chlorine and iodine. As a result of the increasing molecular weight of the halogens down the group, the density and heats of fusion and vaporisation of bromine are again intermediate between those of chlorine and iodine, although all their heats of vaporisation are fairly low (leading to high volatility) thanks to their diatomic molecular structure. The halogens darken in colour as the group is descended: fluorine is a very pale yellow gas, chlorine is greenish-yellow, and bromine is a reddish-brown volatile liquid that freezes at −7.2 °C and boils at 58.8 °C. (Iodine is a shiny black solid.) This trend occurs because the wavelengths of visible light absorbed by the halogens increase down the group. Specifically, the colour of a halogen, such as bromine, results from the electron transition between the highest occupied antibonding πg molecular orbital and the lowest vacant antibonding σu molecular orbital. The colour fades at low temperatures so that solid bromine at −195 °C is pale yellow. Liquid bromine is infrared-transparent. Like solid chlorine and iodine, solid bromine crystallises in the orthorhombic crystal system, in a layered arrangement of Br2 molecules.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.